Abstract
The optimal treatment strategy for men with localised prostatic cancer of low and intermediate risk is an actively evolving field. It is important to strike a balance between maximal oncological control and minimal treatment-related complications, which helps preserve the patients’ quality of life. MR-guided transurethral ultrasound ablation (TULSA) has emerged as a minimally invasive treatment option for this group of patients. This article aims to provide of a background on TULSA technology, a step-by-step procedural guide of MR-guided TULSA and to summarise the current evidence of TULSA in management of localised prostatic cancer, as well as other potential indications.
Graphical Abstract
Similar content being viewed by others
References
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.
Klotz L. Overdiagnosis in urologic cancer. World J Urol. 2022;40(1):1–8.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.
Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(1):10–8.
Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, De La Rosette JJMCH, Lepor H, et al. Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement. Eur Urol. 2023;84(6):547–60.
Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Fütterer JJ, Rovers MM. An updated systematic review on focal therapy in localized prostate cancer: What has changed over the past 5 years? Eur Urol. 2022;81(1):5–33.
Chin YF, Lynn N. Systematic Review of Focal and Salvage Cryotherapy for Prostate Cancer. Cureus. 2022;14(6):e26400.
Anttinen M, Blanco Sequeiros R, Boström PJ, Taimen P. Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.1043688.
Borges RC, Tourinho-Barbosa RR, Glina S, Macek P, Mombet A, Sanchez-Salas R, et al. Impact of focal versus whole gland ablation for prostate cancer on sexual function and urinary continence. J Urol. 2021;205(1):129–36.
Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–36.
Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol. 2021;39(4):1115–9.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol. 2021;205(3):769–79.
Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. MR imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial. J Vasc Interv Radiol. 2020;31(5):740-746.e4.
Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70(3):447–55.
Nair SM, Hatiboglu G, Relle J, Hetou K, Hafron J, Harle C, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. BJU Int. 2021;127(5):544–52.
Peters I, Hensen B, Glandorf J, Gutberlet M, Dohna M, Struckmann S, et al. First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study. BMC Urol. 2023;23(1):142.
Burtnyk M, Hill T, Cadieux-Pitre H, Welch I. Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol. 2015;193(5):1669–75.
Rieke V, Pauly KB. MR thermometry. J Magn Reson Imaging JMRI. 2008;27(2):376–90.
Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M. Prostate tissue analysis immediately following magnetic resonance imaging guided transurethral ultrasound thermal therapy. J Urol. 2007;178(3):1080–5.
Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
Siddiqui K, Chopra R, Vedula S, Sugar L, Haider M, Boyes A, et al. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology. 2010;76(6):1506–11.
Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181–91.
Wysock JS, Rapoport E, Hernandez H, Gogaj R, Lepor H. Biopsy assessment of oncologic control 3 years following primary partial gland cryoablation: a prospective cohort study of men with intermediate-risk prostate cancer. J Urol. 2023;210(3):454–64.
Schmid FA, Schindele D, Mortezavi A, Spitznagel T, Sulser T, Schostak M, et al. Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: safety outcomes and complications. Urol Oncol. 2020;38(4):225–30.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.
Dora C, Clarke GM, Frey G, Sella D. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer: a systematic review. J Endourol. 2022;36(6):841–54.
Anttinen M, Mäkelä P, Viitala A, Nurminen P, Suomi V, Sainio T, et al. Salvage magnetic resonance imaging–guided transurethral ultrasound ablation for localized radiorecurrent prostate cancer: 12-month functional and oncological results. Eur Urol Open Sci. 2020;25(22):79–87.
Anttinen M, Mäkelä P, Nurminen P, Yli-Pietilä E, Suomi V, Sainio T, et al. Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. Scand J Urol. 2020;54(6):481–6.
Elterman D, Li W, Hatiboglu G, Relle J, Zorn KC, Bhojani N, et al. Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation for localized prostate cancer: subgroup analyses in patients with concurrent cancer and benign prostatic hyperplasia. J Endourol. 2021;35(4):497–505.
Lumiani A, Samun D, Sroka R, Muschter R. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol Semin Orig Investig. 2021;39(12):830.e9-830.e16.
Nair SM, Stern N, Dewar M, Siddiqui K, Smith E, Gomez JA, et al. Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy. Scand J Urol. 2020;54(3):215–9.
Ghai S, Finelli A, Corr K, Chan R, Jokhu S, Li X, et al. MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase ii trial. Radiology. 2021;298(3):695–703.
Ehdaie B, Tempany CM, Holland F, Sjoberg DD, Kibel AS, Trinh QD, et al. MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: a phase 2b multicenter study. Lancet Oncol. 2022;23(7):910–8.
Benitez CM, Steinberg ML, Cao M, Qi XS, Lamb JM, Kishan AU, et al. MRI-guided radiation therapy for prostate cancer: the next frontier in ultrahypofractionation. Cancers. 2023;15(18):4657.
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human and Animal Rights
This article does not contain any studies with human participants or animals performed by any of the authors. Formal Institutional Board Approval is waived for this type of study.
Informed Consent
For this type of study formal consent is not required. For this type of study consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 (MP4 11901 KB)
Supplementary file2 (MP4 57277 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fung, K.F.K., Cazzato, R.L., Tricard, T. et al. MR-Guided Transurethral Ultrasound Ablation (TULSA)—An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer. Cardiovasc Intervent Radiol 47, 689–701 (2024). https://doi.org/10.1007/s00270-024-03696-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-024-03696-y